Three new adenosine deaminase mutations that define a splicing enhancer and cause severe and partial phenotypes: implications for evolution of a CpG hotspot and expression of a transduced ADA cDNA

Human Molecular Genetics
I SantistebanM L Schroeder

Abstract

We report three novel adenosine deaminase (ADA) mutations with interesting implications. A Somali child with severe combined immunodeficiency disease (SCID) had reduced ADA mRNA in T cells and was homozygous for the nonsense mutation Q3X. Unexpectedly, her healthy father was a compound ADA heterozygote whose second allele carried a 'partial' mutation, R142Q, due to a G-->A transition of a CpG dinucleotide. A C-->T transition of the same CpG produced a nonsense mutation, R142X, in two homozygous Canadian Mennonite infants with SCID. The severe and healthy phenotypes associated with R142X and R142Q, the high frequency of 'partial' ADA mutations arising from CpGs in healthy individuals of African descent and the presence of CAA (glutamine) at codon 142 in murine ADA, suggest selection for replacement of this CpG hotspot by CpA during ADA evolution. R142X, located within a purine-rich segment at nt 62/116 of exon 5, caused skipping of the exon, possibly by disrupting a splicing enhancer. Absence of exon 5 in T cell ADA mRNA and low ADA activity in T cells and erythrocytes obtained at age 18-22 months from one of the Mennonite children, indicate limited expression of a normal ADA cDNA from retrovirally transduced CD34+ umbilical cor...Continue Reading

Citations

Feb 27, 2001·Medicinal Research Reviews·G CristalliE Camaioni
Apr 7, 1992·Biochimica Et Biophysica Acta·R Zidovetzki, D S Lester
Feb 18, 2014·International Journal of Biological Macromolecules·Baljit Singh, R Bala
Apr 5, 2002·Trends in Genetics : TIG·Javier F Cáceres, Alberto R Kornblihtt
Sep 23, 2003·Current Opinion in Immunology·Michael S Hershfield
Nov 7, 1998·Mutation Research·C R Valentine
May 23, 1996·The New England Journal of Medicine·M E BollingerH M Lederman
Dec 20, 2002·DNA and Cell Biology·Peter StoilovStefan Stamm
Aug 16, 2001·Proceedings of the National Academy of Sciences of the United States of America·J G ChangH Li
May 25, 2010·Immunology and Allergy Clinics of North America·Chaim M Roifman
Aug 10, 2015·Clinical Immunology : the Official Journal of the Clinical Immunology Society·Stuart P AdamsH Bobby Gaspar
Feb 5, 2008·The Journal of Allergy and Clinical Immunology·Chaim M RoifmanKaren Mandel
Sep 4, 2007·Pediatric Neurology·Yehuda Nofech-MozesChaim M Roifman
Apr 16, 1998·American Journal of Human Genetics·S HoffmeyerW Krone
Aug 1, 1997·American Journal of Human Genetics·T A Cooper, W Mattox
Apr 29, 1998·American Journal of Human Genetics·S MazoyerG M Lenoir
Oct 3, 1998·American Journal of Human Genetics·F X Arredondo-VegaM S Hershfield
Oct 6, 2016·European Journal of Human Genetics : EJHG·Luisa AzevedoDavid N Cooper
Oct 12, 2013·Current Opinion in Allergy and Clinical Immunology·Eyal GrunebaumChaim M Roifman
Jan 29, 2020·Clinical and Experimental Immunology·L Murguia-FavelaE Grunebaum
Mar 16, 2004·The Journal of Biological Chemistry·Mario Gonzalez-GronowSalvatore V Pizzo
Aug 2, 2003·Critical Reviews in Clinical Laboratory Sciences·Anne-Marie LambeirIngrid De Meester
Aug 26, 1998·Human Mutation·P K RoganT D Schneider
Feb 13, 2001·The Journal of Immunology : Official Journal of the American Association of Immunologists·T ArigaY Sakiyama
Apr 1, 1997·Molecular and Cellular Biology·L R CoulterT A Cooper

❮ Previous
Next ❯

Related Concepts

Related Feeds

CREs: Gene & Cell Therapy

Gene and cell therapy advances have shown promising outcomes for several diseases. The role of cis-regulatory elements (CREs) is crucial in the design of gene therapy vectors. Here is the latest research on CREs in gene and cell therapy.